References
1. Mucenski ML, Taylor BA, Ihle JN,
et al. Identification of a common ecotropic viral integration site,
Evi-1, in the DNA of AKXD murine myeloid tumors. Mol Cell Biol.1988; 8:301-308.
2. Morishita K, Parker DS, Mucenski ML, Jenkins NA, Copeland NG, Ihle
JN. Retroviral activation of a novel gene encoding a zinc finger protein
in IL-3-dependent myeloid leukemia cell lines. Cell. 1988;
54:831-840.
3. Laricchia-Robbio L, Nucifora G. Significant increase of self-renewal
in hematopoietic cells after forced expression of EVI1. Blood
Cells Mol Dis. 2008; 40:141-147.
4. Kataoka K, Sato T, Yoshimi A, et al. Evi1 is essential for
hematopoietic stem cell self-renewal, and its expression marks
hematopoietic cells with long-term multilineage repopulating activity.J Exp Med. 2011; 208:2403-2416.
5. Goyama S, Yamamoto G, Shimabe M, et al. Evi-1 is a critical regulator
for hematopoietic stem cells and transformed leukemic cells. Cell
stem cell. 2008; 3:207-220.
6. Hinai AA, Valk PJ. Review: Aberrant EVI1 expression in acute myeloid
leukaemia. Br J Haematol. 2016; 172:870-878.
7. Morishita K, Parganas E, William CL, et al. Activation of EVI1 gene
expression in human acute myelogenous leukemias by translocations
spanning 300-400 kilobases on chromosome band 3q26. Proc Natl Acad
Sci U S A. 1992; 89:3937-3941.
8. Russell M, List A, Greenberg P, et al. Expression of EVI1 in
myelodysplastic syndromes and other hematologic malignancies without
3q26 translocations. Blood. 1994; 84:1243-1248.
9. Balgobind BV, Lugthart S, Hollink IH, et al. EVI1 overexpression in
distinct subtypes of pediatric acute myeloid leukemia. Leukemia.2010; 24:942-949.
10. Barjesteh van Waalwijk van Doorn-Khosrovani S, Erpelinck C, van
Putten WL, Valk PJ, van der Poel-van de Luytgaarde S, Hack R, et al.
High EVI1 expression predicts poor survival in acute myeloid leukemia: A
study of 319 de novo AML patients. Blood. 2003; 101:837-845.
11. Groschel S, Lugthart S, Schlenk RF, et al. High EVI1 expression
predicts outcome in younger adult patients with acute myeloid leukemia
and is associated with distinct cytogenetic abnormalities. J Clin
Oncol. 2010; 28:2101-2107.
12. Wu X, Wang H, Deng J, Zheng X, Ling Y, Gong Y. Prognostic
significance of the EVI1 gene expression in patients with acute myeloid
leukemia: A meta-analysis. Ann Hematol. 2019; 98:2485-2496.
13. Qin YZ, Zhao T, Zhu HH, et al. High EVI1 expression predicts poor
outcomes in adult acute myeloid leukemia patients with intermediate
cytogenetic risk receiving chemotherapy. Med Sci Monit . 2018;
24:758-767.
14. Konantz M, Andre MC, Ebinger M, et al. EVI-1 modulates leukemogenic
potential and apoptosis sensitivity in human acute lymphoblastic
leukemia. Leukemia. 2013; 27:56-65.
15. Su G, Lian X, Tan D, et al. Aberrant expression of ecotropic viral
integration site-1 in acute myeloid leukemia and acute lymphoblastic
leukemia. Leuk Lymphoma. 2015; 56:472-479.
16. De Weer A, Poppe B, Cauwelier B, et al. Screening for EVI1: Ectopic
expression absent in T-cell acute lymphoblastic leukemia patients and
cell lines. Cancer Gene Cytogenet. 2006; 171:79-80.
17. Vasyutina E, Boucas JM, Bloehdorn J, et al. The regulatory
interaction of EVI1 with the TCL1A oncogene impacts cell survival and
clinical outcome in CLL. Leukemia. 2015; 29:2003-2014.
18. Stevens A, Hanson D, de Leonibus C, et al. EVI1 expression in
childhood acute lymphoblastic leukaemia is not restricted to MLL and
BCR/ABL rearrangements and is influenced by age. Blood Cancer J.2014; 4:e179.
19. Cui L, Li ZG, Chai YH, et al. Outcome of children with newly
diagnosed acute lymphoblastic leukemia treated with CCLG-ALL 2008: The
first nation-wide prospective multicenter study in china. Am J
Hematol. 2018; 93:913-920.
20. Wang Y, Zeng HM, Zhang LP. ETV6/RUNX1-positive childhood acute
lymphoblastic leukemia in China: Excellent prognosis with improved BFM
protocol. Ital J Pediatr. 2018; 44:94.
21. Qin YZ, Jiang Q, Xu LP, et al. The prognostic significance of Wilms’
tumor gene 1 (WT1) expression at diagnosis in adults with Ph-negative B
cell precursor acute lymphoblastic leukemia. Ann Hematol. 2019;
98:2551-2559.
22. Beillard E, Pallisgaard N, van der Velden VH, et al. Evaluation of
candidate control genes for diagnosis and residual disease detection in
leukemic patients using ’real-time’ quantitative reverse-transcriptase
polymerase chain reaction (RQ-PCR) - a Europe against cancer program.Leukemia. 2003; 17:2474-2486.
23. Den Boer ML, van Slegtenhorst M, De Menezes RX, et al. A subtype of
childhood acute lymphoblastic leukaemia with poor treatment outcome: A
genome-wide classification study. Lancet Oncol. 2009; 10:125-34.
24. Dickstein J, Senyuk V, Premanand K, et al. Methylation and silencing
of miRNA-124 by EVI1 and self-renewal exhaustion of hematopoietic stem
cells in murine myelodysplastic syndrome. Proc Natl Acad Sci U S
A. 2010; 107:9783-9788.
25. Liu L, Wang J, Jiang Y, et al. EVI1 expression predicts outcome in
higher-risk myelodysplastic syndrome patients. Leuk Lymphoma.2018; 59:2929-2940.
26. Daghistani M, Marin D, Khorashad JS, et al. EVI-1 oncogene
expression predicts survival in chronic-phase CML patients resistant to
imatinib treated with second-generation tyrosine kinase inhibitors.Blood. 2010; 116:6014-6017.
27. Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children.N Engl J Med. 2015; 373:1541-52.
28. Schrappe M, Hunger SP, Pui CH, et al. Outcomes after induction
failure in childhood acute lymphoblastic leukemia. N Engl J Med.2012; 366:1371-1381.
29. Ho PA, Alonzo TA, Gerbing RB, et al. High EVI1 expression is
associated with MLL rearrangements and predicts decreased survival in
paediatric acute myeloid leukaemia: A report from the children’s
oncology group. Br J Haematol. 2013; 162:670-677.